Precision Monitoring for a
Leading Men’s Health Challenge
The challenge.
Prostate cancer is the second most common cancer in men globally. Yet current monitoring tools, like PSA blood tests or invasive biopsies, often lack specificity, are performed infrequently, and can lead to overtreatment or missed progression. Clinicians need better tools to distinguish between indolent and aggressive disease in real time.
The opportunity.
KIFFIK’s non-invasive ISF platform offers continuous or on-demand biomarker monitoring that could detect early biochemical changes associated with disease onset, progression, or treatment response. By bypassing the need for repeated blood draws or delayed lab tests, the platform supports personalized surveillance strategies and more confident clinical decisions.
Clinical application:
-
Early detection and screening for high-risk populations
-
Monitoring treatment efficacy and therapeutic resistance
-
Active surveillance of low-risk prostate cancer without invasive biopsies
Potential biomoarkers:
-
Prostate-Specific Antigen (PSA)
-
PCA3 (Prostate Cancer Antigen 3)
-
Alpha-methylacyl-CoA racemase (AMACR)
-
Circulating tumor DNA (ctDNA) for mutation profiling
-
Interleukin-8 (IL-8) and other inflammation markers